Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INM-755 cream on epidermal wounds in healthy volunteers
NL-OMON49368Phase 1Completed
- Sponsor
- InMed Pharmaceuticals Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabinol topical and cannabinol in epidermolysis bullosa (EB) (3 arms), sponsored by InMed Pharmaceuticals Inc. Primary endpoints: Incidence of local treatment-emergent adverse events, Incidence of systemic treatment-emergent adverse events and 10 more. Started Jul 2020; status: completed.
02
Drugs
cannabinol topicalcannabinol
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON49368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49368.